Maybe that's a clue as to why this company, which allegedly has $16-26m in yearly sales, is considering merging with an OTC company that, thanks to auditor problems, is delinquent and will have to restate a couple years of filings.
Couple all that with the private company also needing to undergo a proper audit, and the chances of this merger ever finalizing begin to look rather slim.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.